Valiant Organics Q3 FY26 Standalone Profit Up 8.4% to ₹606.36 Lakhs
Valiant Organics reported Q3 FY26 standalone net profit of ₹606.36 lakhs, up 8.4% year-on-year. Revenue from operations was ₹15,906.97 lakhs. Nine-month standalone profit reached ₹1,923.82 lakhs. Consolidated profit for Q3 FY26 was ₹364.45 lakhs. The company recognized an exceptional item of ₹572.08 lakhs related to an insurance claim.
The announcement of quarterly financial results is a material event for investors, impacting stock valuation and investment decisions. The profit growth contributes to this impact.
The standalone net profit has shown a year-on-year increase for the quarter, indicating positive financial performance.
Valiant Organics Limited announced its Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 13, 2026, following the recommendation of the Audit Committee.
For the quarter ended December 31, 2025, the standalone net profit stood at ₹606.36 lakhs, an increase from ₹559.62 lakhs in the same period last year. Revenue from operations for the quarter was ₹15,906.97 lakhs.
For the nine months ended December 31, 2025, the standalone net profit was ₹1,923.82 lakhs. The company also reported an exceptional item of ₹572.08 lakhs during the nine months, which relates to a fire insurance claim settlement for the Sarigam Division fire incident in FY 2022-23.
The consolidated net profit for the quarter ended December 31, 2025, was ₹364.45 lakhs. For the nine months ended December 31, 2025, the consolidated net profit was ₹1,750.92 lakhs.
The company also noted the allotment of 15,000 equity shares to eligible employees on November 29, 2025, under the Valiant Employees Stock Option Plan, 2022, and mentioned the ongoing monitoring of the impact of New Labour Codes.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.